Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that a Capital Markets Meeting will be arranged for investors, analysts and journalists, on Thursday 16 October, at 2pm - 3.30pm CEST, in Stockholm.
CEO Niklas Prager will give an update on the company’s strategy and capital structure.
Time: Thursday 16 October, at 2pm - 3.30pm CEST
Venue: Conference Center Nio Rum, Hamngatan 2, Stockholm
Invitation for: Institutional investors, analysts and media
The event will also be available on-line via Audiocast accessible through Medivir’s website; www.medivir.com
Registration for investors, analysts and journalists
To participate, please register at; firstname.lastname@example.org, or by phone to +46 8 407 64 82, no later than 13 October.
For further information, please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292.
Medivir is an emerging and profitable research-based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals. Medivir receives royalties from Johnson & Johnson’s global sales of the hepatitis C pharmaceutical, Olysio. In addition, revenues for sales of Olysio in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science, targeting different disease areas. The company’s current research and development focus is within infectious diseases, osteoarthritis, neuropathic pain and oncology. Medivir is listed on the Nasdaq OMX Stockholm Mid Cap List.